Site icon europebriefnews

COVID Vaccine to be Approved for Children Aged 5 to 11



Pfizer has officially submitted a demand to the US government to approve the use of its COVID vaccine for children aged five to 11.

In its official application, the company said its research shows no adverse side effects for the age group. Bur, it recommends smaller dose.

Pfizer said its research showed that young children should get a third of the vaccine dose.

After two doses, five to 11-year-olds developed virus-fighting antibody levels just as strong as teens and young adults get from regular-strength shots, the company said.

Pfizer further studied the lower dose in 2,268 volunteers aged five to 11, and has said there were no serious side effects.

However, the study is not large enough to detect any extremely rare side effects, such as the heart inflammation that has sometimes occurred after the second dose of the regular-strength vaccine, mostly in young men.

New Zealand has earlier reported its first death linked to the Pfizer Covid-19 vaccine.

The health ministry declared that a woman suffered a rare heart muscle inflammation side effect after receiving her first batch.

Pfizer COVID Media Team Refused to Comment

But, the Pfizer media team in New Zealand did not immediately reply to an emailed request for comment.

The coroner is currently dealing with the case and we don’t know the cause of death, the health ministry said.

New Zealand is battling an outbreak of the Delta variant of Covid-19 after nearly six months of being virus free.

It reported 53 new cases on Monday, taking the total number of infections in the current outbreak to 562.

The authorities declared a nationwide lockdown earlier this month to beat the spread of the Delta variant.

Exit mobile version